© Yendry Ventura-Carmenate et al, 2021
Although clinical aspects of COVID-19 patients have been widely reported and their management has increased tremendously, safe and effective medications are still lacking. Different types of stem cells have been considered 'candidates' in several therapies. Adult stem cells play a key role in maintaining tissue homeostasis, and are most likely present at high concentrations in the bloodstream of COVID-19 patients in response to exuberant inflammatory processes.
The challenege in adult stem cell therapy is the lack of well-established procedures for stem cell characterization without altering their phenotypes and functions. To over these challenges, Ventura-Carmenate and colleagues developed a patented method for isolating an autologous peripheral blood non-hematopoietic enriched stem cell cocktail (PB-NHESC-C) to be administered by the nebulization route.
In this study, Ventura-Carmenate and colleagues assess the safety and efficacy of PB-NHESC-C stem cell cocktail nebulization as an add-on therapy to standard care for SARS-CoV-2-infected patients.
© enotmaks / Fotolia
Translational Medicine Communications is an interdisciplinary forum for all scientifically valid research from across translational medicine. We publish research that focuses on the biology of disease, as well as preclinical and basic research that is closely associated with medicine. Translational Medicine Communications will also consider reviews, methodology articles, protocols and commentaries.
Our aim is to improve transparency and reproducibility within translational medicine, which is why we consider research papers regardless of outcome or significance of findings, as well as protocols for future research. We aim to serve the translational science community by publishing all scientifically valid and technically sound articles and we are dedicated to facilitating the communication between basic and clinical science.
Translational Medicine Communications is the companion journal to Journal of Translational Medicine.
Journal of Translational Medicine considers articles focusing on information derived from human experimentation to optimise the communication between basic and clinical science.
Dr. Marincola is Global Head of Research at Kite Pharma, Santa Monica, California. He was previously President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation; Chief Research Officer at Sidra Research, Qatar; and Tenured Investigator at the National Institutes of Health, Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine and is the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is also an award winning fiction author of The Wise Men of Pizzo and Cat Behind the Window.
Speed
37 days to first decision for all manuscripts
35 days to first decision for reviewed manuscripts only
62 days from submission to acceptance
20 days from acceptance to publication
Usage
116,990 Downloads (2021)
90 mentions